We are live on ! Find out more
ADVM

Adverum Biotechnologies
ADVM

Delisted

ADVM was delisted on the 8th of December, 2025.

Back to rankings

0 hedge funds and large institutions have $0 invested in Adverum Biotechnologies in 2025 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 50 closing their positions.

New
Increased
Maintained
Reduced
Closed

67.07% less ownership

Funds ownership: 67.07% → 0% (-67%)

100% less funds holding

Funds holding: 50 → 0 (-50)

100% less funds holding in top 10

Funds holding in top 10: 4 → 0 (-4)

100% less capital invested

Capital invested by funds: $63.8M → $0 (-$63.8M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 50

Holders
–
Holders Change
-50
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
50
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
BCM
BML Capital Management
Indiana
-$13.9M
2
PWA
Principia Wealth Advisory
Texas
-$9.41M
3
FLSM
Frazier Life Sciences Management
California
-$9.41M
4
TCM
TCG Crossover Management
California
-$7.56M
5
Vanguard Group
Vanguard Group
Pennsylvania
-$3.95M
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
26
Morgan Stanley
New York
– -$79.5K -17,555 Closed
Citadel Advisors
27
Citadel Advisors
Florida
– -$78.2K -17,267 Closed
D.E. Shaw & Co
28
D.E. Shaw & Co
New York
– -$77.7K -17,153 Closed
Royal Bank of Canada
29
Royal Bank of Canada
Ontario, Canada
– -$61K -13,465 Closed
VPIM
30
Vanguard Personalized Indexing Management
California
– -$58K -12,805 Closed
XT
31
XTX Topco
Cayman Islands
– -$57.3K -12,655 Closed
Squarepoint
32
Squarepoint
New York
– -$51.1K -11,271 Closed
UBS Group
33
UBS Group
Switzerland
– -$25.3K -5,585 Closed
Bank of America
34
Bank of America
North Carolina
– -$16.4K -3,614 Closed
Fidelity Investments
35
Fidelity Investments
Massachusetts
– -$8.76K -1,933 Closed
Osaic Holdings
36
Osaic Holdings
Arizona
– -$7.69K -1,689 Closed
Jones Financial Companies
37
Jones Financial Companies
Missouri
– -$4.51K -1,000 Closed
BNP Paribas Financial Markets
38
BNP Paribas Financial Markets
France
– -$2.45K -540 Closed
PWA
39
Physician Wealth Advisors
Utah
– -$984 -217 Closed
JP Morgan Chase
40
JP Morgan Chase
New York
– -$824 -182 Closed
AF
41
Allworth Financial
California
– -$463 -102 Closed
SS
42
SBI Securities
Japan
– -$381 -84 Closed
PA
43
Parallel Advisors
California
– -$227 -50 Closed
Wells Fargo
44
Wells Fargo
California
– -$136 -30 Closed
Barclays
45
Barclays
United Kingdom
– -$96 -21 Closed
GIA
46
GHP Investment Advisors
Colorado
– -$91 -20 Closed
AAP
47
Arax Advisory Partners
Colorado
– -$86 -19 Closed
Deutsche Bank
48
Deutsche Bank
Germany
– -$5 -1 Closed
SIS
49
Sound Income Strategies
Florida
– -$5 -1 Closed
1
2

ADVM Hedge Fund Activity: Q4 2025 in Review

0 of the 8,227 institutional investors tracked by Wall St. Rank reported a position in Adverum Biotechnologies (ADVM) for Q4 2025, worth a combined $0 — down 100% from $63.8M a quarter earlier.

Sellers outnumbered buyers: 50 funds closed out of ADVM and 0 opened new positions — a net loss of 50 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was BML Capital Management, exiting entirely with an estimated $13.9M sold.

  • 0 institutional investors held Adverum Biotechnologies (ADVM) as of Q4 2025, down from 50 in Q3 2025.
  • Funds reported $0 of Adverum Biotechnologies stock for Q4 2025, down 100% quarter-over-quarter.
  • 0 funds opened new Adverum Biotechnologies positions in Q4 2025 and 50 closed out, a net change of -50 holders.
  • The largest Adverum Biotechnologies seller in Q4 2025 was BML Capital Management, an estimated $13.9M sold.

Based on aggregated 13F filings for Q4 2025.